Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms.

Autor: Senapati J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Arani N; Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Oran B; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Shpall E; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Popat U; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Champlin R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Arora S; Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Issa G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Patel K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Hammond D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Haddad FG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. ndaver@mdanderson.org.
Jazyk: angličtina
Zdroj: Haematologica [Haematologica] 2024 Dec 12. Date of Electronic Publication: 2024 Dec 12.
DOI: 10.3324/haematol.2024.286465
Abstrakt: In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic decisions and prognostication. This retrospective analysis included patients with newly diagnosed MDS (>5% blasts) and AML with TP53 mutation(s) treated at MD Anderson Cancer Center. We factored patient age, TP53 aberration burden, therapy intensity and use of venetoclax in the AML subgroup, and allogeneic hematopoietic stem cell transplantation (HSCT) to interrogate outcomes. TP53 was annotated as high-risk (TP53HR) if >1 mutation, one mutation + allelic deletion or a single mutation with variant allele frequency (VAF) ≥40%; TP53 low risk (TP53LR) included a single TP53 mutation VAF.
Databáze: MEDLINE